Survival Benefit May Position Zaltrap To Compete With Avastin In Second-Line CRC
This article was originally published in The Pink Sheet Daily
Full results of the trial will show how Sanofi-Aventis/Regeneron's VEGF Trap performs in patients who have been on Avastin, as well as how the survival advantage stacks up against Avastin.
You may also be interested in...
Zaltrap gains FDA approval in metastatic colorectal cancer but must compete against several strongly entrenched treatments – Avastin, Vectibix and Erbitux.
Erbitux wins FDA approval for first-line metastatic colorectal cancer negative for KRAS mutations detected with a companion diagnostic specifically approved for the drug. In theory, earlier use could help shore up sales. But the drug faces a tough competitor in the dominant Avastin and new products are on the near horizon.
Roche presented a mixed sales picture across regions and products in a first quarter 2012 earnings call. Management highlighted a busy regulatory quarter with two new NME launches and five positive Phase III trials and filings, but also reported generic and competitive threats to key products.